Organon & Co (NYSE: OGN) has a price-to-earnings ratio that is above its average at 3.35x. The stock has a 36-month beta value of 0.57. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for OGN is 258.99M, and at present, short sellers hold a 6.16% of that float. On July 01, 2025, the average trading volume of OGN was 5.71M shares.
OGN) stock’s latest price update
The stock of Organon & Co (NYSE: OGN) has decreased by -1.83 when compared to last closing price of 9.86.Despite this, the company has seen a loss of -1.22% in its stock price over the last five trading days. globenewswire.com reported 2025-06-30 that SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April 30, 2025. Organon is a global healthcare company with a primary focus on improving the health of women throughout their lives.
OGN’s Market Performance
Organon & Co (OGN) has seen a -1.22% fall in stock performance for the week, with a 1.47% gain in the past month and a -33.29% plunge in the past quarter. The volatility ratio for the week is 3.19%, and the volatility levels for the past 30 days are at 3.80% for OGN. The simple moving average for the last 20 days is -1.17% for OGN’s stock, with a simple moving average of -32.85% for the last 200 days.
Analysts’ Opinion of OGN
JP Morgan, on the other hand, stated in their research note that they expect to see OGN reach a price target of $20, previously predicting the price at $18. The rating they have provided for OGN stocks is “Underweight” according to the report published on September 06th, 2024.
Goldman gave a rating of “Neutral” to OGN, setting the target price at $16 in the report published on November 03rd of the previous year.
OGN Trading at -1.33% from the 50-Day Moving Average
After a stumble in the market that brought OGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.10% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OGN starting from COX CARRIE SMITH, who purchase 12,469 shares at the price of $8.07 back on May 14 ’25. After this action, COX CARRIE SMITH now owns 12,469 shares of Organon & Co, valued at $100,591 using the latest closing price.
Falcione Aaron, the Chief Human Resources Officer of Organon & Co, purchase 5,500 shares at $8.77 during a trade that took place back on May 07 ’25, which means that Falcione Aaron is holding 62,974 shares at $48,235 based on the most recent closing price.
Stock Fundamentals for OGN
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.57 for the gross margin
The net margin for Organon & Co stands at 0.12. The total capital return value is set at 0.13. Equity return is now at value 254.24, with 5.99 for asset returns.
Based on Organon & Co (OGN), the company’s capital structure generated 0.94 points at debt to capital in total, while cash flow to debt ratio is standing at 0.1. The debt to equity ratio resting at 16.52. The interest coverage ratio of the stock is 2.72.
Currently, EBITDA for the company is 1.61 billion with net debt to EBITDA at 5.61. When we switch over and look at the enterprise to sales, we see a ratio of 1.74. The receivables turnover for the company is 4.32for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
To sum up, Organon & Co (OGN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
